Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04414111 · ClinicalTrials.gov registry record
Highly Suppressive Treg in Delayed and Slow Graft Function After Kidney Transplantation
A clinical trial of Kidney Transplant; Complications and DGF, sponsored by St. Louis University.
- Active
- Registry status
- 180
- Enrollment target
- 2
- Study locations
NCT04414111: Active study of Kidney Transplant; Complications and DGF, sponsored by St. Louis University.
NCT04414111 is a study of Kidney Transplant; Complications and DGF that is active but no longer recruiting, run by St. Louis University. The registered enrollment target is 180 participants, above the 112-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (61% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04414111, a study of Kidney Transplant; Complications and DGF, is active but no longer recruiting, sponsored by St. Louis University.
- ACTIVE NOT RECRUITING
- Registry status
- 180 participants
- Enrollment target
- 2
- Study locations
Study Summary
Delayed/slow graft function is the most common complication after kidney transplantation with an incidence over 20% and is the result of ischemia-reperfusion injury. The increased use of marginal kidney grafts to palliate the organ shortage is leading to a continued rise in the incidence of delayed/slow graft function. Delayed/slow graft function, however, is associated with an increased risk of acute rejection and graft failure. There are currently no clinically accepted biomarkers and no specific treatments for delayed/slow graft function. Regulatory T cells are protective in ischemia-reperfusion injury and rejection by suppressing pathologic immune responses. We hypothesize that the pre-transplant measurement of highly suppressive regulatory T cell is an accurate biomarker for delayed/slow graft function and its immunologic consequences. Ultimately, marginal kidney graft allocation could be directed to regulatory T cell-robust recipients and regulatory T cell-directed therapies could decrease marginal kidney graft discards without increasing delayed/slow graft function or impacting outcomes.
Primary Outcome
Delayed graft function defined as dialysis requirement within the first week after kidney transplant
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Highly suppressive Treg measurement
Study Locations (2)
California
- Loma Linda University Health Transplantation Institute - San Bernardino
Missouri
- Saint Louis University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2020-12-07 |
| Est. Completion | 2027-07-31 |
What the registry record for NCT04414111 still lists
NCT04414111 is an observational study that tracks outcomes without assigning an intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 112-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (61% higher).
The record links to 2 conditions, with Kidney Transplant; Complications appearing as the primary indexed condition, and to 1 intervention - of which Highly suppressive Treg measurement is the first listed.
NCT04414111 reports a single indexed study location in California, Missouri.
Frequently Asked Questions
What is clinical trial NCT04414111 about?
NCT04414111 is a clinical study titled "Highly Suppressive Treg in Delayed and Slow Graft Function After Kidney Transplantation". Delayed/slow graft function is the most common complication after kidney transplantation with an incidence over 20% and is the result of ischemia-reperfusion injury. The increased use of marginal kidney grafts to palliate the organ shortage is leading to a continued rise in the incidence of delayed/...
What is the current status of trial NCT04414111?
This trial is currently active not recruiting. The enrollment target is 180 participants. The study started on 2020-12-07. Estimated completion is 2027-07-31.
What conditions does trial NCT04414111 study?
This clinical trial studies the following conditions: Kidney Transplant; Complications, DGF.
What interventions are being tested in trial NCT04414111?
The interventions under investigation include: Highly suppressive Treg measurement (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04414111?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04414111 being conducted?
This trial has 2 study locations across California, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant; Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04414111's enrollment target sits among peer trials
180 4th of 19 higher than 16 of 19 other Kidney Transplant; Complications trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplant; Complications trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immune Registry for BK in Kidney Transplant Recipients
RECRUITING
-
Feasibility Study for the Comprehensive Overweight/Obesity Management Pre-Kidney Transplant (COMPKT) Program
RECRUITING · NA
-
The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
RECRUITING · Phase 2
-
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
RECRUITING · Phase 3
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Dietary Intervention to Improve Kidney Transplant Outcomes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI